The Impact of JAK2V617F Mutation on Philadelphia-negative Myeloproliferative Neoplasms

Overview

Journal Turk J Med Sci

Specialty General Medicine

Date 2021 Sep 6

PMID 34482679

Citations 2

Authors

Ezgi Sahin

Ipek Yonal-Hindilerden

Fehmi Hindilerden

Aynur Aday

Meliha Nalcaci

Affiliations

Soon will be listed here.

Abstract

Background: JAK2V617F mutation is expressed in almost all polycthemia vera (PV), 55% of essential thrombocythemia (ET), and 65% of primary myelofibrosis (PMF) patients. Studies investigating phenotypic effects of JAK2V617F mutation on Philadelphianegative myeloproliferative neoplasms (Ph-negative MPNs) have reported controversial results. This study aims to determine the impact of JAK2V617F mutation on clinical phenotype and outcome in Ph-negative MPNs.

Methods: Clinical correlates and long-term prognostic relevance of the JAK2V617F mutation were analyzed in 410 Phnegative MPNs-170 ET, 135 PV, 105 PMF- from two institutions and followed for a mean of 76.7 months (SD 62.1) (mean 87 months (SD 67.8), 70.4 months (SD 56.4), 68 months (SD 57.4), respectively for ET, PV, and PMF). Two hundred and twenty-eight patients were genotyped for JAK2V617F mutation using the JAK2 Ipsogen MutaScreen assay, which involves allele-specific polymerase chain reaction (PCR), and 182 patients were genotyped using melting curve analysis.

Results: In PV patients, JAK2V617F mutation was associated with higher rate in females, lower hemoglobin (Hgb) level, higher leukocyte and platelet count and higher prevalence of thrombosis (p = 0.008, p = 0.018, p = 0.001, p = 0.001, and p = 0.035, respectively). In ET patients, JAK2V617F mutation was associated with higher Hgb and hematocrit (Hct) levels and lower platelet count (p = 0.001, p = 0.001, and p = 0.001, respectively). JAK2V617F-negative ET patients showed a trend towards higher rate of leukemic transformation (p = 0.061). JAK2V617F mutation-positive PMF patients had higher leukocyte count, greater spleen size and showed a trend towards higher Hgb level (p = 0.019, p = 0.042, and p = 0.056, respectively). Among PMF patients with JAK2V617F mutation, the rate of female patients was lower (p = 0.001). Overall survival (OS) in Dynamic International Prognostic Scoring System (DIPSS) - plus high risk PMF patients was shorter compared to the other risk groups (p = 0.001). Leukemia-free survival (LFS) was shorter in DIPSS - plus high risk PMF patients than the other risk groups (p = 0.005). In the entire cohort of Ph-negative MPN patients, JAK2V617F mutation was associated with higher leukocyte count, higher Hgb and Hct levels and lower platelet count, higher frequency of phlebotomies, a trend towards older age, a trend towards greater spleen size, a trend towards a higher prevalence of risk factors for cardiovascular diseases and thrombosis (p = 0.001, p = 0.005, p = 0.001, p = 0.003, p = 0.004, p =0.052, p = 0.056, p = 0.052, and p = 0.059, respectively).

Citing Articles

Implications of Clonal Hematopoiesis in Hematological and Non-Hematological Disorders.

Zhang Q, Yim R, Lee P, Chin L, Li V, Gill H Cancers (Basel). 2024; 16(23).

PMID: 39682303 PMC: 11640442. DOI: 10.3390/cancers16234118.

Splanchnic Vein Thrombosis in Myelofibrosis-An Underappreciated Hallmark of Disease Phenotype.

Beleva E Int J Mol Sci. 2023; 24(21).

PMID: 37958701 PMC: 10649007. DOI: 10.3390/ijms242115717.

References

Borowczyk M, Wojtaszewska M, Lewandowski K, Gil L, Lewandowska M, Lehmann-Kopydlowska A . The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. Thromb Res. 2015; 135(2):272-80. DOI: 10.1016/j.thromres.2014.11.006. View

Vannucchi A, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A . Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008; 22(7):1299-307. DOI: 10.1038/leu.2008.113. View

Tefferi A, Lasho T, Schwager S, Steensma D, Mesa R, Li C . The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol. 2005; 131(3):320-8. DOI: 10.1111/j.1365-2141.2005.05776.x. View

Helbig G, Wieczorkiewicz A, Wozniczka K, Wisniewska-Piaty K, Rusek A, Kyrcz-Krzemien S . The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis. Med Oncol. 2012; 29(4):2379-84. DOI: 10.1007/s12032-012-0190-3. View

Hsiao H, Yang M, Liu Y, Lee C, Yang W, Liu T . The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia. Exp Hematol. 2007; 35(11):1704-7. DOI: 10.1016/j.exphem.2007.08.011. View

Lieu C, Wu H, Hon Y, Tsai W, Yang C, Wang C . Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders. Intern Med J. 2008; 38(6):422-6. DOI: 10.1111/j.1445-5994.2007.01589.x. View

Saki N, Shirzad R, Rahim F, Saki Malehi A . Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2 mutations and laboratory findings: a meta-analysis. Clin Transl Oncol. 2017; 19(7):874-883. DOI: 10.1007/s12094-017-1618-1. View

Zhu J, Liu Y, Liu P, Jia M, Cheng J, Zhao L . [JAK2V617F mutation in the patients with myeloproliferative disorder and its relation with clinical characteristics]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011; 19(4):916-20. View

Bertozzi I, Peroni E, Coltro G, Bogoni G, Cosi E, Santarossa C . Thrombotic risk correlates with mutational status in true essential thrombocythemia. Eur J Clin Invest. 2016; 46(8):683-9. DOI: 10.1111/eci.12647. View

10.

Posfai E, Marton I, Kiraly P, Kotosz B, Kiss-Laszlo Z, Szell M . JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis. Pathol Oncol Res. 2015; 21(3):751-8. DOI: 10.1007/s12253-014-9885-4. View

11.

Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E . Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood. 2009; 114(8):1477-83. DOI: 10.1182/blood-2009-04-216044. View

12.

Hoffman R, Prchal J, Samuelson S, Ciurea S, Rondelli D . Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. Biol Blood Marrow Transplant. 2007; 13(1 Suppl 1):64-72. DOI: 10.1016/j.bbmt.2006.11.003. View

13.

Tefferi A, Lasho T, Huang J, Finke C, Mesa R, Li C . Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008; 22(4):756-61. DOI: 10.1038/sj.leu.2405097. View

14.

Wolanskyj A, Lasho T, Schwager S, McClure R, Wadleigh M, Lee S . JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol. 2005; 131(2):208-13. DOI: 10.1111/j.1365-2141.2005.05764.x. View

15.

Yonal-Hindilerden I, Daglar-Aday A, Akadam-Teker B, Yilmaz C, Nalcaci M, Yavuz A . Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms. J Blood Med. 2015; 6:157-75. PMC: 4459634. DOI: 10.2147/JBM.S78826. View

16.

Palandri F, Ottaviani E, Salmi F, Catani L, Polverelli N, Fiacchini M . JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients. Leuk Lymphoma. 2009; 50(2):247-53. DOI: 10.1080/10428190802688152. View

17.

Chao H, Fan Z, Zhang R, Shen Y, Chen W, Fei H . [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms]. Zhonghua Zhong Liu Za Zhi. 2009; 31(7):510-4. View

18.

Zhang S, Qiu H, Fischer B, Li W, Duan L, Sun X . JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera. Leuk Lymphoma. 2008; 49(4):696-9. DOI: 10.1080/10428190701885537. View

19.

Qin Y, Wang X, Zhao C, Wang C, Yang Y . The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis. Int J Hematol. 2015; 102(2):170-80. DOI: 10.1007/s12185-015-1808-y. View

20.

Campbell P, Scott L, Buck G, Wheatley K, East C, Marsden J . Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005; 366(9501):1945-53. DOI: 10.1016/S0140-6736(05)67785-9. View